News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lentigen Corporation Awarded Phase I SBIR Grant for Hepatitis C Vaccine


12/9/2009 10:02:33 AM

GAITHERSBURG, Md,, Dec. 9 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business innovation research (SBIR) grant for a program on "A Novel Method of Generating Hepatitis C Virus-Like Particles using Lentivirus". In this program, Lentigen will collaborate with Epixis SA (Paris, France).

Epixis SA has previously designed rVLPs pseudotyped with one or both of the HCV envelope proteins E1 and E2. Mice primed with a recombinant viral vector expressing E1 and E2 can mount unprecedented neutralizing humoral immune responses upon boosting with such pseudotyped rVLPs. Before reaching the clinic, their large scale production calls for a new efficient and safe system.

Boro Dropulic, Lentigen's President and Chief Scientific Officer, commented, "The collaboration represents the integration of two important technologies to generate highly immunogenic HepC VLPs. The project is consistent with our strategy of applying Lentigen's technology in diseases of high unmet therapeutic need."

Lentigen Corporation



Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES